Cipla partners with Qilu to license, supply Keytruda biosimilar in US
Cipla's US subsidiary Invagen Pharmaceuticals will market Qilu Pharmaceutical's QL2107, a biosimilar to Merck's cancer drug Keytruda, in the United States
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.